Page 137 - 《中国药房》2026年4期

[21] DE FRANCHIS R. Expanding consensus in portal hyper‐ 3758.
tension：report of the Baveno Ⅵ Consensus Workshop： [32] MORT J F，DAVIS J P E，MAHORO G，et al. Rates of
stratifying risk and individualizing care for portal hyper‐ bleeding and discontinuation of direct oral anticoagulants
tension[J]. J Hepatol，2015，63（3）：743-752. in patients with decompensated cirrhosis[J]. Clin Gastro‐
[22] TRAGER M H，GORDON E R，HUMPHREYS T R，et al. enterol Hepatol，2021，19（7）：1436-1442.
Part 1：management of antithrombotic medications in [33] CHOU T S，LIN Y，TSAI M L，et al. Efficacy and safety
dermatologic surgery[J]. J Am Acad Dermatol，2025，92 of direct oral anticoagulants versus warfarin in patients
（3）：389-404. with atrial fibrillation and liver cirrhosis[J]. J Clin Gastro‐
[23] LU S X，CHEN J，ZHANG R，et al. Comparative effec‐ enterol，2025，59（9）：901-909.
tiveness of warfarin in cirrhotic patients with non- [34] CARLIN S，CUKER A，GATT A，et al. Anticoagulation
symptomatic portal vein thrombosis：a multicenter，ran‐ for stroke prevention in atrial fibrillation and treatment of
domized controlled trial[J]. Expert Rev Gastroenterol venous thromboembolism and portal vein thrombosis in
Hepatol，2024，18（1/2/3）：5-12. cirrhosis：guidance from the SSC of the ISTH[J]. J
[24] GAO Z J，LI S S，ZHAO J R，et al. Anticoagulation Thromb Haemost，2024，22（9）：2653-2669.
therapy early is safe in portal vein thrombosis patients [35] ZHOU H N，WU M D，YU S X，et al. Comparison of the
with acute variceal bleeding：a multi-centric randomized efficacy and safety between rivaroxaban and dabigatran in
controlled trial[J]. Intern Emerg Med，2023，18（2）： the treatment of acute portal vein thrombosis in cirrhosis
513-521. [J]. BMC Gastroenterol，2023，23（1）：329.
[25] WU J L，DENG X Y，LUO J Y，et al. Update in the treat‐ [36] AI M H，DONG W G，TAN X P，et al. Efficacy and safety
ment of cirrhotic patients with portal vein thrombosis[J]. study of direct-acting oral anticoagulants for the treatment
Clin Mol Hepatol，2025，31（4）：1139-1166. of chronic portal vein thrombosis in patients with liver
[26] GHAZALEH S，BERAN A，ABURAYYAN K，et al. Effi‐ cirrhosis[J]. Eur J Gastroenterol Hepatol，2020，32（10）：
cacy and safety of anticoagulation in non-malignant portal 1395-1400.
vein thrombosis in patients with liver cirrhosis：a systematic [37] NAGAOKI Y，AIKATA H，DAIJYO K，et al. Efficacy
review and meta-analysis[J]. Ann Gastroenterol，2021，34 and safety of edoxaban for treatment of portal vein throm‐
（1）：104-110. bosis following danaparoid sodium in patients with liver
[27] SENZOLO M，PIANO S，SHALABY S，et al. Compari‐ cirrhosis[J]. Hepatol Res，2018，48（1）：51-58.
son of fondaparinux and low-molecular-weight heparin in [38] LV Y，BAI W，LI K，et al. Anticoagulation and transjugu‐
the treatment of portal vein thrombosis in cirrhosis[J]. Am lar intrahepatic portosystemic shunt for the management
J Med，2021，134（10）：1278-1285. of portal vein thrombosis in cirrhosis：a prospective obser‐
[28] SPYROPOULOS A C，DOUKETIS J D. Standardized vational study[J]. Am J Gastroenterol，2021，116（7）：
management of direct oral anticoagulants for elective pro‐ 1447-1464.
cedures[J]. JAMA Netw Open，2025，8（2）：e2458739. [39] HANAFY A S，ABD-ELSALAM S，DAWOUD M M.
[29] 刘双，赵东强. 利伐沙班治疗肝硬化门静脉血栓的研究 Randomized controlled trial of rivaroxaban versus warfa‐
进展[J]. 临床肝胆病杂志，2023，39（7）：1721-1727. rin in the management of acute non-neoplastic portal vein
[30] CHENG C W，HUA J，XIONG L. Comparison of the effi‐ thrombosis[J]. Vascul Pharmacol，2019，113：86-91.
cacy and safety of direct oral anticoagulants and warfarin [40] DIESVELD M M E，PIJNENBURG D W M J，
in cirrhotic patients：a systematic review and meta-analysis WEERSINK R A，et al. Recommendations for the safe use
[J]. Clin Appl Thromb Hemost，2024，30：107602962413- of direct oral anticoagulants in patients with cirrhosis
01402. based on a systematic review of pharmacokinetic，pharma‐
[31] XIAO X L，ZHU W G，DAI Q X. Direct oral anticoagu‐ codynamic and safety data[J]. Eur J Clin Pharmacol，
lants versus traditional anticoagulation in cirrhotic patients 2024，80（6）：797-812.
with portal vein thrombosis：updated systematic review[J]. （收稿日期：2025-10-11 修回日期：2026-02-09）
Clin Appl Thromb Hemost，2024，30：1076029624130- （编辑：舒安琴）

中国药房 2026年第37卷第4期 China Pharmacy 2026 Vol. 37 No. 4 · 539 ·